Teratogenic risks from exposure to illicit drugs

Obstet Gynecol Clin North Am. 2014 Jun;41(2):229-39. doi: 10.1016/j.ogc.2014.02.008. Epub 2014 Mar 29.

Abstract

Substance use is prevalent in the United States, especially in the reproductive age population. Even though a reduction in substance use may occur during pregnancy, some women may not alter their drug use patterns until at least pregnancy is confirmed. For these reasons, a large number of fetuses are exposed to illicit substances, including during critical stages of organogenesis. Associating illicit drug use with eventual pregnancy outcome is difficult. This article presents issues pertaining to limitations with published investigations about fetal risks and describes the most current information in humans about fetal effects from specific illicit substances.

Keywords: Addiction; Fetal effects; Illicit drug use; Pregnancy complications; Teratogenic risk.

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced
  • Child Behavior Disorders / chemically induced*
  • Child Behavior Disorders / prevention & control
  • Female
  • Fetal Growth Retardation / chemically induced*
  • Fetal Growth Retardation / prevention & control
  • Humans
  • Illicit Drugs / adverse effects*
  • Infant, Newborn
  • Perinatal Care
  • Postnatal Care
  • Pregnancy
  • Pregnancy Complications / chemically induced*
  • Pregnancy Outcome
  • Prenatal Exposure Delayed Effects
  • Substance Abuse Detection
  • Substance-Related Disorders / complications*
  • Substance-Related Disorders / epidemiology*
  • Substance-Related Disorders / prevention & control
  • Teratogens*
  • United States / epidemiology

Substances

  • Illicit Drugs
  • Teratogens